2024

1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

   AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions

   International Journal of Antimicrobial Agents, Vol. 63, Núm. 5

3. Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales

   Antimicrobial agents and chemotherapy, Vol. 68, Núm. 11, pp. e0092424

4. Characterization of an outbreak caused by Elizabethkingia miricola using Fourier-transform infrared (FTIR) spectroscopy

   European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 4, pp. 797-803

5. Corrigendum to “Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions” [International Journal of Antimicrobial Agents Volume 63, Issue 5 (2024) 107150] (International Journal of Antimicrobial Agents (2024) 63(5), (S0924857924000682), (10.1016/j.ijantimicag.2024.107150))

   International Journal of Antimicrobial Agents

6. Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain

   European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 2, pp. 279-296

7. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

   The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

8. Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

   Infection

9. Epidemiology, resistance genomics and susceptibility of Acinetobacter species: results from the 2020 Spanish nationwide surveillance study

   Eurosurveillance, Vol. 29, Núm. 15

10. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 10, pp. 2591-2597

11. Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa

    The Journal of antimicrobial chemotherapy, Vol. 79, Núm. 11, pp. 3023-3028

12. In vitro activity of cefiderocolagainst European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations

    Microbiology Spectrum, Vol. 12, Núm. 8

13. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

14. Mitomycin C as an Anti-Persister Strategy against Klebsiella pneumoniae: Toxicity and Synergy Studies

    Antibiotics, Vol. 13, Núm. 9

15. Patients with aggressive B-cell lymphoma receiving CAR T-cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis

    European Journal of Haematology

16. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group

    Clinical Microbiology and Infection

17. Rapid and Simple Morphological Assay for Determination of Susceptibility/Resistance to Combined Ciprofloxacin and Ampicillin, Independently, in Escherichia coli

    Antibiotics, Vol. 13, Núm. 7

18. Regulation of anti-phage defense mechanisms by using cinnamaldehyde as a quorum sensing inhibitor

    Frontiers in Microbiology, Vol. 15

19. Safety and efficacy of personalised versus standard dosing of linezolid in patients with sepsis (SePkLin): a pragmatic, multicentre, randomised, controlled and superiority clinical trial protocol

    BMJ open, Vol. 14, Núm. 10, pp. e087465

20. Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain

    HIV Medicine